Fortress Biotech (FBIO) Stock Price

Fortress Biotech Price

NASDAQ·CLOSED
2.11
​
Market closed

Over the last 10 years Fortress Biotech grew revenue by 53.6% annually, reaching 63.26 M USD. For Fortress Biotech, the net margin of 10.8% is up versus -94.1% a few years ago. The consensus 12-month price target for Fortress Biotech is 5.00 USD, about 137.0% above where the stock trades today. Of 8 analysts, 7 rate the stock a buy — an overall Buy consensus.

Fortress Biotech stock price

Access this data via the Eulerpool API

Fortress Biotech business model & stock analysis

Fortress Biotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel pharmaceutical and biotechnology products. The company is headquartered in New York City, New York and currently employs 93 full-time employees. The company went IPO on 2011-11-17. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies. Fortress has 11 operating subsidiaries that include: 4 commercial stage programs, 25 development stage programs, targeting 6 therapeutic areas: Immuno-oncology, Hematology, Gene Therapy, Pain Management, Rare Diseases and Dermatology. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies. Fortress subsidiaries include Aevitas Therapeutics, Avenue Therapeutics, Caelum Biosciences, Cellvation, Inc., Checkpoint Therapeutics, Cyprium Therapeutics, Helocyte, Inc., Journey Medical Corporation, Mustang Bio and Tamid Bio, Inc.

Frequently asked questions about Fortress Biotech

Analysts currently set an average price target of 5.00 USD for the Fortress Biotech stock (median: 5.00 USD), implying +137.0 % versus the latest price. The consensus is based on 8 analyst ratings.

8 analysts currently rate the Fortress Biotech stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Fortress Biotech to generate revenue of 78.79 M USD and earnings per share of 2.21 USD.

Converted at the current exchange rate, the Fortress Biotech share trades at 1.88 EUR (2.11 USD).

The Fortress Biotech share (FBIO) is listed on 4 stock exchanges, including: NASDAQ (FBIO), Frankfurt (CNB.F), München (CNB.MU), Düsseldorf (CNB.DU).

The expected revenue of Fortress Biotech is 78.79 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Fortress Biotech is 79.15 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Fortress Biotech is currently 0.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Fortress Biotech stock.

The price-to-sales ratio (P/S) of Fortress Biotech is currently 0.96. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Fortress Biotech stock.

The Eulerpool Quality Score for Fortress Biotech is 3/10.

The ISIN of Fortress Biotech is US34960Q3074. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Fortress Biotech is A14SJV. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Fortress Biotech is FBIO. The ticker symbol is used to trade Fortress Biotech shares on the stock exchange.

Fair ValueTerminal
1.88 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue per Employee
811,051.28 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 17, 2011
ISIN
US34960Q3074
Cusip
34960Q109
Sedol
BWT3FG4
Market capitalization
65.49 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
0.83
P/Ee 2027
-2.43
P/S
P/Se
0.96
EV/EBIT
—
P/B Ratio
1.31
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
5.49 %
Last updated Oct 11, 2026, 10:36 PM

Fortress Biotech Ticker

DÜSSELDORF · CNB.DUFRANKFURT · CNB.FMUNICH · CNB.MUNASDAQ · FBIO